Chemours Co (CC) earnings date
Feb 18, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 27% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 7 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 2, 2026 | after close | 33 | 8-K |
| Q2 FY2026 | Tue, Aug 4, 2026 | after close | 35 | 8-K |
| Q1 FY2026 | Tue, May 5, 2026 | after close | 35 | 8-K |
| Q4 FY2025 | Thu, Feb 19, 2026 | after close | 50 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | after close | 37 | 8-K |
| Q2 FY2025 | Tue, Aug 5, 2025 | after close | 36 | 8-K |
| Q1 FY2025 | Tue, May 6, 2025 | after close | 36 | 8-K |
| Q4 FY2024 | Tue, Feb 18, 2025 | before open | 49 | 8-K |
What they guided beta
| Q3 FY2026 | "See the corresponding reconciliation referenced in footnote #2. 4 Restricted cash approximated $103 million of the end of the third quarter of 2026, reflected primarily the PFAS Insurance Escrow and will be further described in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026." exhibit |
| Q3 FY2026 | "Fourth Quarter 2026 Outlook In the fourth quarter, the Company expects consolidated Net Sales to decrease in the range of 5% to 10%, sequentially, driven by seasonality in TSS and TT, with consolidated Adjusted EBITDA expected to range between $160 million and $185 million." exhibit |
| Q3 FY2026 | "Full Year 2026 Outlook The Company expects 2026 Net Sales to grow approximately 2% over 2025, with Adjusted EBITDA between $775 million and $800 million." exhibit |
| Q3 FY2026 | "Capital expenditures are anticipated to be between $220 million and $230 million, with overall Free Cash Flow Conversion above 15%, which includes receipt of $150 million in restricted cash related to the PFAS insurance proceeds MOU in connection with the finalization of the JCO with the State of New Jersey, partially offset by legal settlement payments in the year related to the finalization of the JCO with the State of New Jersey and the announced settlement with the State of North Carolina during the third quarter of 2026 as well as the taxes associated with the Kuan Yin property sale now c" exhibit |
| Q3 FY2026 | "The Company now anticipates achieving a Net Leverage ratio below 4.2x in 2026." exhibit |
| Q2 FY2026 | "APM Performance Solutions Net Sales grew 8% year-over-year, underscoring momentum and mix shift towards high value specialty products serving data center and semiconductor end market “Our second quarter results reflect disciplined execution across our portfolio, with Adjusted EBITDA near the high end of our guidance range and Free Cash Flows above our expectations despite a dynamic macroeconomic environment,” said Denise Dignam, Chemours President and CEO." exhibit |
| Q2 FY2026 | "The volume decline was primarily driven by lower TSS Opteon™ blends aftermarket refrigerant sales, compared with elevated demand in Q2 2025 driven by the initial aftermarket channel fill associated with stationary technology AC transition under the U.S. AIM Act, as well as lower volumes associated with the APM SPS Capstone™ line closure completed in the third quarter of 2025." exhibit |
| Q2 FY2026 | "The decrease was driven by the anticipated higher APM costs associated with the recently resolved outage at the Washington Works site, as well as lower sales from APM’s SPS Capstone™ line closure completed in the third quarter of 2025, partially offset by pricing increases across all segments. 4 On a diluted earnings per share basis." exhibit |
| Q2 FY2026 | "The decrease in volumes was primarily attributable to lower stationary AC aftermarket refrigerant sales of TSS Opteon™ blends in North America, compared with elevated demand in Q2 2025 driven by the initial aftermarket channel fill associated with the stationary technology AC transition under the U.S. AIM Act, partially offset by higher Freon™ prices, primarily in automotive applications." exhibit |
| Q2 FY2026 | "The Company anticipates further debt repayments in 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/CC
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/CC
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/CC/"><img src="https://veritasdata.dev/embed/CC.svg" alt="CC earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/CC/)
Script
<script async src="https://veritasdata.dev/embed/CC.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/CC"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.